Abstract 922P
Background
Genomic instability is an hallmark of cancer that has been associated to immune evasion, cancer progression and multidrug resistance. MOSCATO (NCT) was a prospective clinical trial evaluating the clinical benefit of high-throughput genomic analyses in patients with advanced solid tumors. In this study we investigated a genomic instability score based on somatic copy number alterations as determined by Single Nucleotide Polymorphism (SNP) array as a biomarker for head and neck cancer patients.
Methods
Extracted DNA from fresh frozen tumor was analyzed using high-resolution Affymetrix Cytoscan® HD array whereas extracted DNA from FFPE samples was analyzed using the Affymetrix Oncoscan® CNV assay. The absolute copy-number (ACN) profile was generated by ASCAT v3.1 through EaCoN v0.3.6 (https://github.com/gustaveroussy/EaCoN, PMID 36669143) on R v4.1.1 and then the genomic instability score (GIS) was estimated as the sum of the segment length multiplied by the absolute difference between segment copy number and the ASCAT estimated sample ploidy. This sum is reported to the reference genome length. In parallel, somatic mutation were assessed with a NGS panel covering including at least 75 critical oncogenes and tumor suppressor genes.
Results
SNP array data were available for 58 patients out of the 111 with head and neck cancers. 38 were men, 34 had squamous histology (SCC), 13 cystadenocarcinoma (ACC) and 11 other types (adenocarcinoma, mucinous carcinoma). Patients with SCC had higher GIS (median 0.53 for SCC vs 0.05 for ACC and 0.40 for others). At genomic level, the presence of TP53 (p < 0.001) and ATM (p 0.056) were associated with higher GIS. This was confirmed also after adjusting for histology. Conversely, GIS score was not associated with age. Patients with SCC that were positive for HPV (n=11) had lower GIS respect to HPV negatives (n=14, 0.24 vs 0.85, p 0.05) Higher GIS score was associated with decreased OS after adjusting for histology (HR 1.87, 95% CI 1.31 - 2.65, p < 0.001).
Conclusions
Genomic instability score based on SNP array copy number alterations profile is associated with worse prognosis in patients with carcinoma of the head and neck. Higher GIS score is found in squamous cell carcinomas and is associated with mutations in genes involved in cell cycle control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03